← All trials
NCT04738955
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 1, 2021
- Primary completion
- Jan 1, 2023
- Completion date
- Oct 1, 2023
- First posted
- Feb 4, 2021
- Last posted
- Feb 4, 2021
- Enrollment
- 230
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Shandong Provincial HospitalLead sponsor
- Shandong Provincial HospitalReponsible party - principal investigator
- Shandong Provincial HospitalStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.